Please use this identifier to cite or link to this item:
|Title:||Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.|
Antibodies, Monoclonal, Humanized
Chemotherapy-Induced Febrile Neutropenia
|Citation:||Ann. Oncol..2017 04;(28)4:761-768|
|Abstract:||Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.